Epigenomics AG
EPGNF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -1.5% | -2.7% | -47.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 89.6% | 89.8% | 92.9% | 71.6% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 283.2% | 3,764.9% | -2,922.9% | -3,225.4% |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 2,801.6% | 2,760.4% | -3,761.4% | -4,172.4% |
| EPS Diluted | 2.2 | 2.2 | -3.09 | -6.55 |
| % Growth | 0% | 171.2% | 52.8% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |